Methamphetamine Abuse Clinical Trial
Official title:
Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
This is a double-blind, placebo-controlled, randomized clinical trial in which 360 individuals with moderate or severe MUD will be randomly assigned at a 1:1 ratio to receive either 1) extended release naltrexone (XR-NTX; as Vivitrol®) plus once daily oral extended release bupropion (BUP-XL) tablets (the XR-NTX/BUP-XL group) or 2) both the matching injection placebo (iPLB) and once daily oral placebo (oPLB) tablets (the iPLB/oPLB group). The study intervention consists of a 12-week treatment phase. It is hypothesized that the XR-NTX/BUP-XL arm will be associated with a greater number of "responders," defined as participants who provide at least 3 MA-negative urine drug screens (UDS) out of 4 samples obtained during the evaluation period (i.e., Weeks 11-12) of the 12-week long treatment phase, relative to the iPLB/oPLB arm. Secondary objectives include evaluating the effect of the extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) arm compared to the iPLB/oPLB arm on safety, other substance use outcomes, depression scores, quality of life, overall functioning, clinic attendance, and medication adherence. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
| Completed |
NCT03226223 -
Pharmacogenetics of Naltrexone for Stimulant Abuse
|
Phase 2 | |
| Not yet recruiting |
NCT05593796 -
Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder
|
N/A | |
| Completed |
NCT02907853 -
Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa
|
N/A | |
| Recruiting |
NCT04616625 -
Cardiovascular Effects of Prenatal Methamphetamine Exposure
|
||
| Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
| Recruiting |
NCT05700994 -
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
|
N/A | |
| Completed |
NCT04109014 -
FASTLANE II: Reducing Sex, Drug, and Mental Health Risk
|
N/A | |
| Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT01822132 -
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
|
N/A | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
| Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 |